Jennifer E. Amengual
Columbia University Irving Medical Center(US)
Publications by Year
Research Areas
Lymphoma Diagnosis and Treatment, Histone Deacetylase Inhibitors Research, Viral-associated cancers and disorders, Chronic Lymphocytic Leukemia Research, CAR-T cell therapy research
Most-Cited Works
- → Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission(2017)173 cited
- → HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL(2011)151 cited
- → A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma(2017)133 cited
- → Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study(2019)127 cited
- → Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1–2 trial(2017)113 cited
- → Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412(2021)106 cited
- → Emerging EZH2 Inhibitors and Their Application in Lymphoma(2018)98 cited
- → Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era(2019)95 cited
- → Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma(2015)90 cited
- → Preclinical Pharmacologic Evaluation of Pralatrexate and Romidepsin Confirms Potent Synergy of the Combination in a Murine Model of Human T-cell Lymphoma(2015)76 cited